Finding drugs that work well with cancer immunotherapy
Identifying drug synergistic with cancer immunotherapy
['FUNDING_OTHER'] · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · NIH-10895519
This study is looking for new drugs that can make cancer immunotherapy work better for patients with late-stage cancers like melanoma, bladder, kidney, and lung cancer, so they can have more personalized and effective treatment options instead of just traditional chemotherapy.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR (nih funded) |
| Locations | 1 site (ALBUQUERQUE, UNITED STATES) |
| Trial ID | NIH-10895519 on ClinicalTrials.gov |
What this research studies
This research aims to identify drugs that can enhance the effectiveness of cancer immunotherapy using advanced artificial intelligence techniques. By focusing on late-stage cancer patients, particularly those with melanoma, bladder, kidney, and lung cancers, the project seeks to develop personalized treatment strategies that move away from traditional chemotherapy. The approach combines computational biology with immuno-oncology to systematically prioritize drug candidates for clinical trials. Patients may benefit from more effective treatment options tailored to their specific cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced melanoma, bladder, kidney, or lung cancer who are seeking alternative treatment options.
Not a fit: Patients with early-stage cancers or those not diagnosed with melanoma, bladder, kidney, or lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments that improve patient outcomes.
How similar studies have performed: Other research has shown promise in using AI to enhance cancer treatment strategies, indicating that this approach could yield significant advancements.
Where this research is happening
ALBUQUERQUE, UNITED STATES
- UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR — ALBUQUERQUE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SAHU, AVINASH DAS — UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
- Study coordinator: SAHU, AVINASH DAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, Anti-Cancer Agents